Skip to main content
OpenTrials
Completed

NCT Number: NCT02871908

Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial

The aim of this study is to assess the effect of Lactobacillus reuteri DSM 17938 administration for the prevention of diarrhea and AAD in children.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Paediatrics, The Medical University of Warsaw, Poland

Warsaw, 02-091, Poland

About this study

Introduction:

Addition of some probiotics appears to reduce the risk of antibiotic-associated diarrhea (AAD). Effects of probiotics are strain specific, thus the efficacy and safety of each probiotic strain should be established separately. We aim to assess the effect of Lactobacillus reuteri DSM 17938 administration for the prevention of diarrhea and AAD in children.

Methods and analysis:

A total of 250 children younger than 18 years treated with antibiotics will be enrolled into a double-blind, randomized placebo-controlled trial in which they will additionally receive L reuteri DSM 17938 at a dose 2 x 10^8 colony-forming units or an identically appearing placebo, orally, twice daily, for the entire duration of antibiotic treatment. The primary outcome measures will be the frequency of diarrhea and AAD. Diarrhea will be defined according to one of 3 definitions: (a) ≥3 loose or watery stools per day for a minimum of 48 hours during antibiotic treatment; (b) ≥3 loose or watery stools per day for a minimum of 24 hours during antibiotic treatment; (c) ≥2 loose or watery stools per day for a minimum of 24 hours during antibiotic treatment. AAD will be diagnosed in cases of diarrhea, defined clinically as above, caused by C. difficile or for otherwise unexplained diarrhea (i.e. negative laboratory stool tests for infectious agents).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age younger than 18 years;
  • oral or intravenous antibiotic therapy which started within 24 hours of enrollment;
  • signed informed consent.

Exclusion criteria

  • pre-existing acute or chronic diarrhea,
  • history of chronic gastrointestinal disease (e.g., inflammatory bowel disease, cystic fibrosis, celiac disease, food allergy) or other severe chronic disease (e.g., neoplastic diseases), immunodeficiency,
  • use of probiotics within 2 weeks prior to enrollment,
  • use of antibiotics within 4 weeks prior to enrollment,
  • prematurity, and exclusive breastfeeding.

Treatment and study plan

Lactobacillus reuteri DSM 17938

Drug

Lactobacillus reuteri DSM 17938 twice daily 2 x 10^8

Placebo

Drug

Placebo

Primary outcomes

  1. frequencies of diarrhea and antibiotic associated diarrhea

    Time frame: during antibiotic treatment, an average of 10 days and 7 days of follow up

    Three different definitions of diarrhea will be used, as the definitions of diarrhea/AAD in published studies vary. These will include diarrhea defined as: (a) ≥3 loose or watery stools per day for a minimum of 48 hours during antibiotic treatment; (b) ≥3 loose or watery stools per day for a minimum of 24 hours during antibiotic treatment, and (c) ≥2 loose or watery stools per day for a minimum of 24 hours during antibiotic treatment. AAD will be diagnosed in cases of diarrhea, defined clinically as above, caused by C. difficile or for otherwise unexplained diarrhea (i.e., negative laboratory stool tests for infectious agents). In all cases, loose or watery stools will correspond to scores of 5 to 7 on the BSF scale or A-consistency on the AISS.

Secondary outcomes

  1. infectious diarrhea

    Time frame: during antibiotic treatment, an average of 10 days and 7 days of follow up

    rotavirus, adenovirus, norovirus, Salmonella, Shigella, Campylobacter, Yersinia and C. difficile

  2. the need for discontinuation of the antibiotic treatment

    Time frame: during antibiotic treatment, an average of 10 days

  3. the need for hospitalization to manage the diarrhea (in outpatients)

    Time frame: during antibiotic treatment, an average of 10 days and 7 days of follow up

  4. the need for intravenous rehydration in any of the study groups

    Time frame: during antibiotic treatment, an average of 10 days and 7 days of follow up

  5. adverse events

    Time frame: during antibiotic treatment, an average of 10 days and 7 days of follow up

Sponsors and collaborators

Lead sponsor

Medical University of Warsaw

Other

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Aug 18, 2016
Registry last updated
Mar 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.